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ABSTRACT 
 
Objective: To determine the association between biomarkers of ovarian reserve and luteal phase 
deficiency. 
Methods: This is a secondary analysis of data from a prospective time-to-conceive cohort study 
performed at the University of North Carolina. Women aged 30-44 years without a history of 
infertility completed daily menstrual diaries. Exposures of interest included early follicular phase 
serum levels of antimüllerian hormone (AMH), follicle stimulating hormone (FSH), inhibin B, 
and estradiol (serum samples collected at enrollment). The primary outcome was luteal phase 
deficiency as defined by luteal bleeding (≥ 1 day of spotting) or a short luteal phase length (≤ 11 
days). Covariates of interest included age, race, previous miscarriages, previous pregnancies, and 
hormonal contraception use.  GEE models were used to estimate the association between 
biomarkers of ovarian reserve and luteal phase deficiency. 
Results: Overall, 755 women provided information on 2,171 menstrual cycles and serum for 
measurement of at least one biomarker of ovarian reserve. There were 2,096 cycles from 754 
women in the luteal phase bleeding cohort, of which 40% experienced luteal phase bleeding. 
After adjusting for age, race, previous miscarriages, and previous pregnancies, diminished 
ovarian reserve was not statistically significantly associated with luteal phase bleeding. Low 
early follicular phase FSH levels increased the odds of luteal phase bleeding (OR 1.84; 95% CI 
1.25, 2.71), as did high early follicular phase estradiol levels (OR 1.59; 95% CI 1.26, 2.01). A 
total of 608 cycles from 286 women were in the luteal phase length cohort, of which 13% had a 
short luteal phase. After adjusting for age, there was no statistically significant association 
between diminished ovarian reserve and a short luteal phase. The risk of a short luteal phase 
decreased with increasing inhibin B (OR 0.61; 95% CI 0.45, 0.81).  
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Conclusions: Diminished ovarian reserve is not associated with luteal phase deficiency, as 
defined by luteal phase bleeding or a short luteal phase, in women of older reproductive age. 
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Background 
The concept of luteal phase deficiency (LPD) is very controversial in the realm of 
reproductive medicine. LPD is thought to be associated with infertility, recurrent pregnancy loss, 
and irregular menstrual bleeding, but much controversy exists regarding its pathophysiology and 
diagnosis.5,6 Adequate progesterone production by the corpus luteum is required for the 
maintenance of pregnancy.3 Endogenous progesterone produced during the luteal phase 
maintains functional secretory endometrium, allowing for embryo implantation and 
development. LPD results from either a failure of the corpus luteum to produce sufficient 
progesterone or inappropriate endometrial response to normal levels of progesterone.4 Despite 
the uncertainty around the clinical relevance of LPD, understanding the effects of LPD among 
women attempting conception is important. 
Determining the diagnostic criteria for LPD has been difficult. Clinical, histologic, and 
laboratory methods have been proposed.3,5,6 Some studies have identified endometrial biopsy as 
the best diagnostic tool, although recent opinions have found the timing and interpretation of 
these results to be challenging.3–9 Recent studies have suggested simpler clinical methods of 
diagnosing LPD. These include manifestations such as a shortened luteal phase and luteal 
spotting.4–6,9  
As women age, their follicular pool, or ovarian reserve, declines. This decline is typically 
monitored using plasma measurements of hormones such as anti-müllerian hormone (AMH), 
follicle stimulating hormone (FSH), estradiol, and inhibin B.1 Although diminished ovarian 
reserve has not been shown not to affect fertility, some evidence suggests it is associated with 
miscarriage.1   
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Corpus luteum functionality may decrease with declining ovarian reserve, manifesting as 
a luteal phase defect with either a shortened luteal phase or luteal spotting. It is hypothesized that 
diminished ovarian reserve may be associated with luteal phase deficiency, increasing the risk of 
miscarriage without affecting fertility. This study sought to determine the relationship between 
biomarkers of ovarian reserve and LPD as defined by luteal phase bleeding or a short luteal 
phase. 
Methods 
Eligibility and Enrollment 
This is a secondary analysis of data collected from the Time to Conceive (TTC) study, a 
time-to-pregnancy study conducted from April 2008 to August 2016.   Full information on the 
TTC study has been previously published by Steiner et al.1 Eligible study participants included 
English-speaking women aged 30-44 years who were cohabitating with a male partner and had 
been attempting to conceive for ≤ 3 months. Women with known fertility issues (diagnosis of 
polycycstic ovarian syndrome (PCOS), surgically diagnosed endometriosis, history of 
sterilization, known tubal blockage, current or previous use of fertility treatments) or a partner 
with a history of infertility were excluded from the study. Women were also excluded if they had 
used injectable hormonal contraception in the past year or were currently breastfeeding. The 
study was approved by the Institutional Review Board of the University of North Carolina, and 
all participants provided written consent. 
Study participants were screened for eligibility using a standardized questionnaire over 
the phone. If eligible, women completed a questionnaire in order to obtain demographic 
information as well as other factors possibly associated with fertility. Race was self-selected by 
participants from provided categories. Once enrolled, women contacted the study coordinator 
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with their subsequent menses and were scheduled for a study visit on menstrual cycle day 2, 3, or 
4, at which time blood samples were collected. Patients were withdrawn from the study if they 
were lost to follow-up or at the initiation of fertility medication. Women were also withdrawn 
upon request, most commonly because they stopped trying to conceive or were moving. 
Women completed daily menstrual diaries while attempting to conceive, documenting 
information regarding bleeding, medications, intercourse, and pregnancy test results.   Women 
were not required to use ovulation predictor kits (OPK) but were asked to record the results of 
the tests in their diary if they tested for ovulation.  From 2010 until completion of the study, 
women were provided free OPKs (Clear Blue Easy, SPD Swiss Precision Diagnostics GmbH).  
Definition of Key Variables 
The definition of menses consisted of three or more days of spotting or bleeding (with 
one or more days of bleeding) followed by two consecutive days without spotting or bleeding.  
The first day of bleeding during menses was considered to be the first day of a menstrual cycle. 
Luteal phase defects were defined as either luteal phase bleeding or a short luteal phase. Luteal 
phase bleeding was defined as any bleeding or spotting on one or more days of the luteal phase. 
When assessing luteal phase bleeding, timing of the luteal phase was calculated using an OPK. If 
the study participant did not use an OPK, the luteal phase was estimated as spanning the 14 days 
prior to the next documented menses start date. Luteal phase lengths were only assessed in 
women using OPKs. Ovulation was estimated to occur the day after a positive OPK test result. 
The luteal phase was estimated to start on the day of ovulation and end on the last day prior to 
menses. Therefore, the luteal phase length was calculated by subtracting the date of ovulation 
(the day after a positive OPK) from the menses start date. A luteal phase lasting 11 or fewer days 
was defined as a short luteal phase. Luteal phase length cannot be determined during a cycle in 
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which women conceive, therefore women who conceived during their first informative cycle 
were excluded from analysis for the luteal phase length cohort.  
  
Serum Analysis 
Samples were stored at -30˚C and shipped frozen in a single batch to the University of 
Southern California Reproductive Endocrinology Laboratory. There the samples were assayed 
using specific and sensitive assays for AMH (Ultrasensitive AMH ELISA, Ansh, lower limit of 
detection 0.078 ng/ml), FSH (Immulite analyzer, Siemens, Deerfield, IL), estradiol 
(Radioimmunoassay) and inhibin B (ELISA, Ansh Labs, Webster, TX). Interassay coefficients 
of variation ranged from 9-11% for AMH, 4-5% for FSH, and 5-8% for inhibin B.  
Statistical Analysis 
 The primary outcome measure of the study was the presence of a luteal phase defect as 
defined as luteal phase bleeding or a short luteal phase. Luteal phase bleeding was defined as one 
or more days of bleeding at any point during the luteal phase. A short luteal phase was defined as 
a luteal phase lasting 11 or fewer days. Exposure of interests were biomarkers of ovarian reserve 
(AMH, FSH, estradiol, and inhibin B) modeled as continuous variables. The natural logs of 
serum biomarkers were used in models as measurements were not normally distributed. AMH 
and FSH were also considered as categorical variables as informed choices for cut-off points 
were available. The lower AMH cut-off of 0.7 ng/ml was chosen based off of previous 
research.10 The lower FSH cut-off of 4.2 mIU/ml correlates to the bottom tenth percentile of FSH 
measurements. The upper clinical cut-offs of 7.5 ng/ml for AMH and 10 mIU/ml for FSH were 
chosen a priori.  
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Covariates were categorized to simplify interpretation. Age was divided into three 
categories: < 35 years, 35-37 years, and > 37 years. Body mass index (BMI) was also grouped 
into four categories: underweight (< 18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 
kg/m2), and obese (≥ 30 kg/m2). Education level was categorized as having completed a college 
degree or less versus completing some graduate school or more. Marital status was divided into 
married versus other. Women were also asked about recent hormonal contraception use. Original 
questionnaires addressed hormonal contraception use within the past twelve months. The 
modified electronic questionnaire used later in the study allowed the use of hormonal 
contraception within the past three months to be determined. Over 20% of the cohort was 
missing information regarding hormonal contraception use within the last three months, therefore 
this variable was only included for descriptive purposes and was not included in the final models.  
Bivariate analyses were performed to compare women with luteal phase bleeding in their 
first informative cycle versus women without luteal phase bleeding. Additionally, bivariate 
analyses were used to compare women with a short luteal phase in their first informative cycle to 
those with normal luteal phase length. Chi-square statistic and Wilcox Rank sum were used for 
categorical and continuous variables, respectively. Generalized Estimation Equation (GEE) 
models were created to determine the association between measures of ovarian reserve and the 
odds of luteal phase bleeding or a short luteal phase. Covariates found to be associated with the 
outcome in the bivariate analysis were included in the models as potential confounders. Given 
the known association between age and ovarian reserve, the decision was made to adjust all 
models for age regardless of bivariate analysis results.1 The final models for luteal spotting 
adjusted for age, race, previous miscarriages, previous pregnancies, and hormonal contraception 
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use in the past three months. The final models for luteal phase length adjusted only for age. Stata 
(version 15.1) was used for statistical analysis.  
Results 
A total of 1,042 women were enrolled in the TTC study (Figure 1). Of these, 814 women 
had at least one serum measurement of AMH, FSH, estradiol, or inhibin B. Fifty-nine of these 
women did not record menstrual diaries. Overall, 2,171 cycles from 755 women had at least one 
serum measurement and documented menstrual diaries. All 755 women had AMH levels, but 
only 697 women had FSH and inhibin B measurements. There were insufficient quantities to run 
the analysis on six number of samples for estradiol, leaving 691 women with documented 
estradiol measurements. 
A majority of the overall cohort was under 35 years of age (69%) and had a normal BMI 
(61%) (Table 1). Most of the study participants were white (78%), married (93%), and well 
educated. Nearly half of the cohort had previously been pregnant and/or had used hormonal 
contraception within the previous year. Most women had never smoked (77%) or had any prior 
miscarriages (80%). The median AMH was 2.81 ng/ml (IQR 1.45, 5.13), FSH was 6.6 mIU/ml 
(IQR 5.22, 8.2), estradiol was 42.32 pg/ml (IQR 31.63, 58.56), and inhibin B was 70.0 pg/ml 
(IQR 37.31, 101.51).  
A total of 2,096 cycles from 754 women had data on luteal spotting (Figure 1). One study 
participant had a documented luteal length but was missing information regarding luteal spotting. 
Only 374 of the 755 women with serum samples and menstrual diaries used OPKs. In addition, 
88 women conceived during their first cycle therefore having documented menstrual bleeding 
patterns without calculated luteal lengths. This left a total of 608 cycles from 286 women with 
documented luteal lengths. The distribution of the covariates were similar between the luteal 
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phase bleeding (LPB) and luteal phase length (LPL) cohorts, including age, BMI, and median 
biomarker levels.  
Table 2 shows patient characteristics stratified by LBP and LBL cohorts. Of the 754 women 
with documented LPB, 40% (n=303) reported luteal spotting. Age and BMI distributions were 
similar between those women with and without luteal bleeding. Women with LPB were more 
likely to be non-white (26% vs. 20%; p=0.043). Median levels of AMH, FSH, and Inhibin B did 
not significantly differ between those with and without bleeding. However, women with LPB 
had significantly higher estradiol levels (45.1 vs. 40.0 pg/ml; p<0.01). Additionally, women with 
a low FSH (< 4.2 mIU/ml) were more likely to experience luteal phase bleeding (13% vs. 7%; 
p=0.031).  
Of the 286 women in the LPL cohort, 13% (n=36) were found to have short luteal phases in 
their first informative cycle (Table 2). There were no significant differences in demographic 
characteristics between women with a short luteal phase and those with normal luteal lengths. 
Biomarkers of ovarian reserve did not differ between women with and without a short luteal 
phase in their first informative cycle.  
When analyzed as a continuous variable, none of the biomarkers of ovarian reserve were 
statistically significantly associated with the odds of luteal phase bleeding or a short luteal phase 
(Table 3). Diminished ovarian reserve (defined as AMH <0.7 ng/ml or FSH >10 mIU/ml) was 
also not associated with the odds of luteal phase bleeding or a short luteal phase.  
 A low early follicular phase FSH serum level (< 4.2 mIU/ml,) did increase the odds of luteal 
phase bleeding (OR 1.84; 95% CI 1.25, 2.71) compared to normal FSH serum level after 
adjusting for age, race, previous miscarriages, and previous pregnancies (Table 3).  As the early 
follicular phase estradiol level increased, the risk of luteal phase bleeding increased. For every 
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unit increase in the natural log of estradiol, the risk of luteal phase bleeding increased by 
approximately 50% (OR 1.52; 95% CI 1.17, 1.97). 
 
  Women with higher estradiol were also at increased risk of luteal phase bleeding (OR 1.59; 
95% CI 1.26, 2.01). The only biomarker statistically significantly associated with a short luteal 
phase was inhibin B. As early follicular phase inhibin b levels increased, the risk of luteal phase 
bleeding decreased. Specifically, for every unit increase in the natural log of inhibin B, the risk 
of luteal phase bleeding decreased by approximately 40%  (OR 0.61; CI 0.45, 0.81). 
In a sensitivity analysis, luteal phase bleeding was defined as two or more days of luteal 
phase bleeding.  Using this definition, only 17% of women experienced luteal phase bleeding in 
the first informative cycle.  Restricting the definition to two or more days of bleeding 
strengthened the association between diminished ovarian reserve and luteal phase spotting, but 
they remained statistically non-significant.  The association between low FSH and luteal phase 
bleeding was weakened and became statistically non-significant.    
Discussion 
In this study, we found no association between diminished ovarian reserve, as defined by 
low AMH or high FSH, and risk of luteal phase bleeding or a short luteal phase. Interestingly, 
low FSH and high estradiol levels in the early follicular phase did increase the odds of 
experiencing luteal phase bleeding. None of the biomarkers of ovarian reserve were statistically 
significantly associated with a short luteal phase with the exception of early follicular inhibin B. 
As inhibin b increased, the odds of a short luteal phase decreased. 
Ovarian reserve does not appear to be a predictor of luteal spotting or a short luteal phase. 
To our knowledge, no other studies have investigated the association of these biomarkers with 
 12 
menstrual characteristics such as LPD. However, a large body of literature exists on the 
association of diminished ovarian reserve and general menstrual characteristics, such as cycle 
and follicular length.11,12 Vassena et al. found shorter menstrual cycles among women with lower 
ovarian reserve, thought to be due to decreased follicular availability and thus fewer follicular 
waves per cycle.11 Additionally, Gizzo et al. found menstrual cycle length to be a surrogate 
measure for ovarian response to hyperstimulation in women with diminished ovarian reserve. 
Among women with AMH levels below 1.1 ng/ml, shorter menstrual cycles (< 28 days) were 
associated with a weaker ovarian response.12 In both of these studies, the shorter menstrual 
cycles seen with diminished ovarian reserve were attributed to shorter follicular phases. As the 
number of follicles decrease, so does the number of functioning granulosa cells which in turn 
reduces the secretion of inhibin B. This reduction in inhibin B increases FSH production in the 
late luteal and early follicular phase, initiating earlier follicular development, and ultimately 
shortening the follicular phase.12 Although it has been argued that diminished ovarian reserve 
reduces overall menstrual cycle length, our results suggest that reduced ovarian reserve is not 
associated with LPD.   
Our study found lower follicular FSH levels to be associated with an increased risk of 
luteal phase bleeding. This is in agreement with the findings of Scliep et al., who studied 259 
regularly menstruating women aged 18-44 years in order to determine the prevalence of luteal 
phase deficiency and its associated hormone concentrations.9 In this study, women with luteal 
phases shorter than 10 days were found to have significantly lower FSH levels throughout their 
menstrual cycle. It’s been suggested that, secondary to hypothalamic-pituitary-ovarian axis 
alterations, the deficiency of FSH during the follicular phase hinders follicular development and 
subsequent formation and function of the corpus luteum.9,13 However, the relationship of low 
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FSH with luteal phase defects was only seen with luteal phase bleeding. There was no 
association between low FSH and a short luteal phase in our study.  
There was also a statistically significant association seen between follicular estradiol 
levels and luteal phase bleeding. In our study, higher serum estradiol levels appeared to increase 
the risk of luteal phase bleeding; however, estradiol levels were not associated with luteal phase 
length. These findings contrast those of Schliep et al., who found lower follicular and luteal 
estradiol levels in women with biochemical LPD, defined as less than 5 ng/ml maximum 
progesterone, and clinical LPD, defined as luteal phases lasting less than 10 days.9  
Early follicular phase Inhibin B was the only biomarker of ovarian reserve found to be 
statistically significantly associated with a short luteal phase. In this cohort, having decreased 
inhibin B levels increased the odds of a short luteal phase. As previously mentioned, lower 
inhibin B levels have been associated with shorter menstrual cycles in several studies, but this is 
typically contributed to a shortened follicular phase.12,14,15   Inhibin B is secreted during the 
follicular phase, while inhibin A is secreted during the luteal phase.  We did not measure inhibin 
A; however, inhibin B levels may reflect inhibin A levels. Thus women with lower inhibin B 
may also have lower inhibin A levels, leading to a shorter luteal phase.  
Inhibin B is the dominant hormone produced by antral follicles, playing a bigger role in 
the regulation of pituitary FSH during the early follicular phase than inhibin A.16,17 Fully 
functioning granulosa cells decrease as the number of follicles in the ovary decline. In turn, less 
inhibin B is produced, causing an increase in FSH secretion during the late luteal phase, and, as a 
result, there is an earlier initiation of follicle development and a subsequent shortening of the 
follicular phase.12 A lower inhibin B level in the earlier follicular phase could represent poor 
follicular potential and development, leading to less progesterone production, and subsequently 
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causing luteal phase deficiency exhibited as a short luteal phase. Early initiation of follicle 
development may result in higher estradiol levels and lower FSH levels during the early 
follicular phase, which was more commonly observed in women with luteal phase bleeding.    
Thus, inhibin levels may play an important role in maintaining a normal luteal phase. 
This study has several strengths. To our knowledge, this is the first study to examine the 
association between ovarian reserve and luteal phase deficiency. The prospective design of the 
study helped to estimate the prevalence of luteal phase deficiency while minimizing selection 
bias by not enrolling patients based on factors related to exposure variables or the presence of 
luteal phase deficiency. Other advantages of the study design include a large size and a focused 
population. Multiple menstrual cycles were documented for over 750 women, and the age range 
studied (30-44 years) allowed for focus on women at risk for diminished ovarian reserve. 
Menstrual diaries were also completed on a daily basis, allowing for thorough documentation of 
all cycle characteristics and spotting patterns. In addition, luteal phase lengths were confidently 
estimated with OPKs, avoiding the measurement error introduced with self-reported cycle 
lengths.18 Lastly, multiple measures of ovarian reserve were investigated in this study, and 
biomarkers were measured during the early follicular phase in all study participants. This 
minimized the potential measurement bias introduced by fluctuations in serum levels according 
to the phase of the menstrual cycle. 
There were also several limitations to this study. First, a majority of the study participants 
were well-educated, white women, taking away from the generalizability of the study results. 
Second, not all study participants had access to OPKs, therefore only a small portion of the 
overall cohort had documented luteal phase lengths. In addition, the overall cohort consisted of 
women attempting to conceive, which creates a challenge given that luteal phase length cannot 
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be determined in a conception cycle. Women were not required to have regular menstrual cycles 
to participate.  Thus, it may be that some of the episodes of luteal phase spotting are, in fact, 
anovulatory cycles. However, not restricting our cohort to women with regular menstruation, 
makes the study cohort more generalizable.  
Our definition of luteal phase bleeding was not very restrictive. When using our original 
definition of one or more days of bleeding during the luteal phase as identifying luteal phase 
deficiency, the prevalence of luteal phase deficiency was much higher than expected. However, 
our prevalence of a short luteal phase (13%) was similar to that observed in other studies, which  
found 18% , 12.4%, and 8% of women to have luteal phase lengths less than 11 days.4,9,19  
Restricting the definition of luteal phase bleeding in our sensitivity analysis lowered the 
prevalence of luteal phase deficiency to 17%, which is more consistent with prior studies. 
However, even with this more restrictive definition, there was no statistically significant 
association between biomarkers of ovarian reserve and luteal phase deficiency.  
Conclusions 
Diminished ovarian reserve, as measured using biomarkers, does not appear to be a cause of 
luteal phase defects.  However, follicular phase hormone levels of inhibin b, estradiol, and FSH 
do appear to influence luteal phase events, suggesting that luteal phase defects may arise with 
hormonal dysregulation in the follicular phase.   
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Appendix 1 
 
Figure 1: Flow diagram of study enrollment and cohort selection 
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Table 1: Patient characteristics for luteal phase bleeding cohort and luteal phase length cohort 
 
 Overall Luteal Phase Bleeding Cohort 
Luteal Length 
Cohort 
N 755 754 286 
Total Cycles 2,171 2,096 608 
Age (years) 
     < 35 
    35-37 
    ≥ 37 
 
 
525 (69%) 
105 (14%) 
125 (17%) 
 
524 (70%) 
105 (14%) 
125 (17%) 
 
196 (69%) 
38 (13%) 
52 (18%) 
BMI (kg/m2) 
     < 18.5 
     18.5 – 24.9 
     25 – 29.9 
     ≥ 30 
     Missing 
 
 
22 (3%) 
464 (61%) 
154 (20%) 
115 (15%) 
1 (<1%) 
 
21 (3%) 
464 (62%) 
154 (20%) 
114 (15%) 
1 (< 1%) 
 
11 (4%) 
179 (63%) 
54 (19%) 
42 (15%) 
AMH (ng/ml) 
Median (IQR) 
 
2.81 (1.45, 5.13) 2.81 (1.45, 5.13) 2.60 (1.49, 4.97) 
AMH (ng/ml) 
     < 0.7 
     0.7 – 7.5 
     >  7.5 
 
77 (10%) 
576 (76%) 
102 (14%) 
 
 
77 (10%) 
575 (76%) 
102 (14%) 
 
31 (11%) 
220 (77%) 
35 (12%) 
FSH (mIU/ml) 
Median (IQR) 
 
6.6 (5.22, 8.2) 6.61 (5.22, 8.205) 6.7 (5.43, 8.36) 
FSH (mIU/ml) 
     < 4.2 
     4.2-10 
     > 10 
     Missing 
 
 
71 (9%) 
549 (73%) 
77 (10%) 
58 (8%) 
 
71 (9%) 
548 (73%) 
77 (10%) 
58 (8%) 
 
18 (6%) 
205 (72%) 
31 (11%) 
32 (11%) 
Estradiol (pg/ml) 
Median (IQR) 
 
42.32 (31.63, 58.56) 42.24 (31.63, 58.56) 45.27 (31.99, 62.88) 
Inhibin B (pg/ml) 
Median (IQR) 
 
70.0 (37.31, 101.51) 70.04 (37.055, 101.49) 71.7 (37.46, 102.68) 
Race 
     Non-Hispanic Caucasian 
     Other 
 
 
589 (78%) 
166 (22%) 
 
588 (78%) 
166 (22%) 
 
221 (77%) 
65 (23%) 
Education 
     Completed College or Less 
     Post-Grad or More 
 
 
207 (27%) 
548 (73%) 
 
207 (27%) 
547 (73%) 
 
79 (28%) 
207 (72%) 
Marital Status 
     Married 
     Other 
 
 
701 (93%) 
54 (7%) 
 
700 (93%) 
54 (7%) 
 
266 (93%) 
20 (7%) 
Previously Pregnant    
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     Yes 
     No 
 
373 (49%) 
382 (51%) 
373 (49%) 
381 (51%) 
123 (43%) 
163 (57%) 
Previous Miscarriages 
     0 
     1 
     ≥ 2 
 
 
606 (80%) 
111 (15%) 
38 (5%) 
 
605 (80%) 
111 (15%) 
38 (5%) 
 
234 (82%) 
37 (13%) 
15 (5%) 
Ever Smoked 
     Yes 
     No 
 
 
177 (23%) 
578 (77%) 
 
176 (23%) 
578 (77%) 
 
68 (24%) 
218 (76%) 
Hormonal Contraception in 
Past 12 Months 
     Yes 
     No 
 
 
 
346 (46%) 
409 (54%) 
 
 
345 (46%) 
409 (54%) 
 
 
133 (47%) 
153 (54%) 
Hormonal Contraception in 
Past 3 Months 
     Yes 
     No 
     Missing 
 
 
 
175 (29%) 
427 (71%) 
153 
 
 
175 (29%) 
426 (71%) 
153 
 
 
79 (69%) 
173 (31%) 
34 
Thyroid Disease 
     Yes 
     No 
     Missing 
 
 
55 (7%) 
699 (93%) 
1 (< 1%) 
 
55 (7%) 
698 (93%) 
1 (< 1%) 
 
22 (8%) 
264 (92%) 
- 
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Table 2: Cohort demographics by presence or absence of luteal phase bleeding and the presence 
or absence of a short luteal phase in the first informative cycle  
 
 Luteal Phase Bleeding 
No Luteal 
Phase Bleeding 
P-
value 
Short Luteal 
Phase 
Normal Luteal 
Length 
P-
value 
N 303 (40%) 451 (60%) - 36 (13%) 250 (87%) - 
Age (years) 
     < 35 
    35-37 
    ≥ 37 
 
 
208 (69%) 
45 (15%) 
50 (17%) 
 
316 (70%) 
60 (13%) 
75 (17%) 
0.833 
 
27 (75%) 
3 (8%) 
6 (17%) 
 
169 (68%) 
35 (14%) 
46 (18%) 
0.587 
BMI (kg/m2) 
     < 18.5 
     18.5 – 24.9 
     25 – 29.9 
     ≥ 30 
     Missing 
 
 
7 (2%) 
185 (61%) 
64 (21%) 
47 (16%) 
- 
 
14 (3%) 
279 (62%) 
90 (20%) 
67 (15%) 
1 (<1%) 
0.866 
 
2 (6%) 
21 (58%) 
5 (14%) 
8 (22%) 
- 
 
9 (4%) 
158 (63%) 
49 (20%) 
34 (14%) 
- 
0.463 
AMH (ng/ml) 
Median (IQR) 
 
2.86 (1.45, 4.87) 2.79 (1.45, 5.36) 0.973 2.925 (1.56, 4.00) 2.48 (1.47, 5.15) 0.973 
AMH (ng/ml) 
     < 0.7 
     0.7 – 7.5 
     >  7.5 
 
31 (10%) 
228 (75%) 
44 (15%) 
 
46 (10%) 
347 (77%) 
58 (13%) 
 
0.803 
 
4 (11%) 
28 (78%) 
4 (11%) 
 
27 (11%) 
192 (77%) 
31 (12%) 
0.976 
FSH (mIU/ml) 
Median (IQR) 
 
6.47 (5.09, 8.35) 6.71 (5.26, 8.17) 0.741 6.6 (5.09, 8.11) 6.7 (5.53, 8.36) 0.799 
FSH (mIU/ml) 
     < 4.2 
     4.2-10 
     > 10 
     Missing 
 
 
40 (13%) 
208 (69%) 
31 (10%) 
24 (8%) 
 
31 (7%) 
349 (75%) 
46 (10%) 
34 (8%) 
0.031 
 
3 (8%) 
26 (72%) 
4 (11%) 
3 (8%) 
 
15 (6%) 
179 (72%) 
27 (11%) 
29 (12%) 
0.902 
Estradiol (pg/ml) 
Median (IQR) 
 
45.1 (34.6, 60.9) 40.0 (30.4, 55.8) < 0.001 41.0 (29.7, 58.7) 45.6 (32.7, 62.9) 0.342 
Inhibin B (pg/ml) 
Median (IQR) 
 
70.6 (36.4, 103.8) 69.2 (37.7, 100.2) 0.670 55.3 (16.4, 95.0) 74.0 (44.6, 103.2) 0.087 
Race 
     Non-Hispanic Caucasian 
     Other 
 
 
225 (74%) 
78 (26%) 
 
363 (80%) 
88 (20%) 0.043 
 
27 (75%) 
9 (25%) 
 
194 (78%) 
56 (22%) 0.728 
Education 
     Completed College or Less 
     Post-Grad or More 
 
 
87 (29%) 
216 (71%) 
 
120 (27%) 
331 (73%) 0.525 
 
14 (39%) 
22 (61%) 
 
65 (26%) 
185 (74%) 0.106 
Marital Status 
     Married 
     Other 
 
 
277 (91%) 
26 (9%) 
 
423 (94%) 
28 (6%) 0.215 
 
35 (97%) 
1 (3%) 
 
231 (92%) 
19 (8%) 0.289 
Previously Pregnant 
     Yes 
     No 
 
 
139 (46%) 
164 (54%) 
 
234 (52%) 
217 (48%) 0.106 
 
14 (39%) 
22 (61%) 
 
109 (44%) 
141 (56%) 0.593 
Previous Miscarriages 
     0 
     1 
 
250 (83%) 
43 (14%) 
 
355 (79%) 
68 (15%) 
0.177 
 
30 (83%) 
4 (11%) 
 
204 (82%) 
33 (13%) 
0.939 
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     ≥ 2 
 
10 (3%) 28 (6%)  2 (6%) 13 (5%) 
Ever Smoked 
     Yes 
     No 
 
 
76 (25%) 
227 (75%) 
 
100 (22%) 
351 (78%) 0.354 
 
8 (22%) 
28 (78%) 
 
60 (24%) 
190 (76%) 0.815 
Hormonal Contraception in 
Past 12 Months 
     Yes 
     No 
 
 
 
138 (46%) 
165 (54%) 
 
 
207 (46%) 
244 (54%) 
0.924 
 
 
18 (50%) 
18 (50%) 
 
 
115 (46%) 
135 (54%) 
0.653 
Hormonal Contraception in 
Past 3 Months 
     Yes 
     No 
     Missing 
 
 
 
70 (27%) 
187 (73%) 
46 
 
 
105 (31%) 
239 (69%) 
107 
0.380 
 
 
11 (34%) 
21 (66%) 
4 
 
 
68 (31%) 
152 (69%) 
30 
0.693 
Thyroid Disease 
     Yes 
     No 
     Missing 
 
 
17 (6%) 
285 (94%) 
1 (<1 %) 
 
38 (8%) 
413 (92%) 
- 
0.167 
 
2 (6%) 
34 (94%) 
 
20 (8%) 
230 (92%) 0.607 
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Table 3: Measures of association with 95% confidence intervals between biomarkers of ovarian 
reserve and luteal phase bleeding and a short luteal phase. 
 
† Adjusted for age, race, previous miscarriages, previously pregnant 
†† Adjusted for age, race, previous miscarriages, previously pregnant, and hormonal 
contraceptive use in past 3 months 
‡ Adjusted for age 
 
  
 
Luteal Phase Bleeding Short Luteal Phase 
 Unadjusted 
OR (95% CI) 
Adjusted† 
OR (95% CI) 
Adjusted†† 
OR (95% CI) 
Unadjusted 
OR (95% CI) 
Adjusted‡ 
OR (95% CI) 
Log AMH (ng/ml) 1.01 (0.91, 1.12) 0.99 (0.89, 1.11) 0.91 (0.81, 1.03) 1.17 (0.92, 1.48) 1.12 (0.88, 1.42) 
AMH (ng/ml)      
     < 0.7 1.07 (0.72, 1.59) 1.03 (0.69, 1.55) 1.23 (0.78, 1.95) 0.52 (0.20, 1.30) 0.57 (0.22, 1.50) 
     0.7 – 7.5 - - - - - 
     >  7.5 1.00 (0.72, 1.39) 0.97 (0.70, 1.37) 0.89 (0.61, 1.29) 1.29 (0.62, 2.71) 1.23 (0.59, 1.58) 
Log FSH (ng/ml) 0.77 (0.58, 1.03) 0.76 (0.57, 1.02) 0.74 (0.54, 1.00) 0.62 (0.28, 1.37) 0.62 (0.27, 1.39) 
FSH (mIU/ml)      
     < 4.2 1.84 (1.26, 2.68) 1.84 (1.25, 2.71) 2.11 (1.38, 3.22) 1.40 (0.38, 5.13) 1.39 (0.38, 5.06) 
     4.2-10 - - - - - 
     > 10 1.21 (0.82, 1.78) 1.18 (0.80, 1.74) 1.34 (0.65, 1.20) 0.73 (0.31, 1.74) 0.75 (0.31, 1.80) 
Log Estradiol 
(pg/ml) 1.65 (1.30, 2.08) 1.59 (1.26, 2.01) 1.52 (1.17, 1.97) 0.613 (0.32, 1.18) 0.63 (0.32, 1.23) 
Log Inhibin B 
(pg/ml) 0.917 (0.80, 1.05) 0.92 (0.80, 1.05) 0.87 (0.75, 1.02) 0.63 (0.48, 0.83) 0.61 (0.45, 0.81) 
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Table 4: Sensitivity analysis showing measures of association with 95% confidence intervals 
between biomarkers of ovarian reserve and luteal phase bleeding redefined as two or more days 
of spotting during the luteal phase. 
 
 
Luteal Phase Bleeding 
 Unadjusted Adjusted† Adjusted†† 
Log AMH (ng/ml) 1.03 (0.89, 1.20) 1.03 (0.88, 1.20) 0.94 (0.80, 1.11) 
AMH (ng/ml)    
     < 0.7 1.25 (0.74, 2.10) 1.20 (0.68, 2.08) 1.51 (0.81, 2.80) 
     0.7 – 7.5 - - - 
     >  7.5 1.30 (0.87, 1.93) 1.26 (0.84, 1.88) 1.13 (0.71, 1.80) 
Log FSH (ng/ml) 
 0.83 (0.52, 1.31) 0.83 (0.52, 1.31) 0.88 (0.54, 1.45) 
FSH (mIU/ml)    
     < 4.2 1.82 (1.13 2.92) 1.73 (1.07, 2.79) 1.56 (0.89, 2.72) 
     4.2-10 - - - 
     > 10 
 1.45 (0.88, 2.40) 1.43 (0.86, 2.36) 1.61 (0.92, 2.80) 
Log Estradiol (pg/ml) 1.76 (1.31, 2.36) 1.67 (1.24, 2.24) 1.62 (1.16, 2.27) 
Log Inhibin B (pg/ml) 0.94 (0.78, 1.12) 0.94 (0.78, 1.13) 0.93 (0.75, 1.15) 
 
† Adjusted for age, race, previous miscarriages, previously pregnant 
†† Adjusted for age, race, previous miscarriages, previously pregnant, and hormonal 
contraceptive use in past 3 months 
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Appendix 2 
 
Literature Review of the Association Between Serum AMH and Pregnancy Loss 
 
INTRODUCTION 
The average age of first time mothers in the U.S. continues to rise.20 Unfortunately, 
fertility decreases with increasing age, often making it difficult for older women to conceive.21 
As women age, their follicular pool declines. This decline is typically monitored using plasma 
measurements of hormones such as anti-müllerian hormone (AMH), follicle stimulating 
hormone (FSH), estradiol, and inhibin B.1 Granulosa cells secrete less AMH as the follicular 
pool declines, allowing AMH to reflect the number of follicles present in the ovary.1,22 
Therefore, a low serum AMH level is considered to be a biomarker of diminished ovarian 
reserve.1 
There are many possible etiologies for female infertility, such as hormonal imbalances, 
anatomical obstructions, and ovulation dysfunctions.23 Egg quality and quantity are typically 
investigated as well. For years, clinicians have associated diminished ovarian reserve with 
infertility, as both are seen with an increase in age.22  A recent prospective cohort study, 
however, found no association between biomarkers of ovarian reserve and time to conception.1  
Increasing age not only increases a woman’s risk of infertility, but it also puts women 
who are able to conceive at a higher risk of adverse pregnancy events such as miscarriage.24 
Although recent evidence has found no association between biomarkers of diminished ovarian 
reserve and infertility, their association with miscarriage is unclear. AMH already serves many 
clinical uses in reproductive medicine, such as the prediction of menopause as well as oocyte 
yield after ovarian hyperstimulation used in IVF.25 Determining its relationship with miscarriage 
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may allow AMH levels to be used earlier in the work-up of infertility, before the use of 
reproductive assistance. 
Rationale and Objectives: 
Recent evidence suggesting that diminished ovarian reserve does not influence fertility 
raises the question of whether it affects pregnancy outcomes. AMH has been identified as a 
reflection of egg quantity, but it’s association with egg quality and menstrual cycle 
characteristics is unknown. This systematic review aims to address this uncertainty by evaluating 
whether serum AMH levels are associated with pregnancy loss. 
METHODS 
Eligibility Criteria: 
Eligibility criteria are outlined in Table 1. Studies enrolling women of all ages were 
eligible, regardless of country setting. All observational studies were eligible, as long as they 
were focused on human subjects and used serum AMH as a measure of ovarian reserve. A 
variety of definitions for low serum AMH were accepted, although studies with cut-offs greater 
than 1.5 ng/dl were excluded. Included studies must have defined miscarriage as pregnancy loss 
before 20 weeks gestation.  
Studies have shown the role of AMH in predicting pregnancy outcomes after assisted 
reproductive technologies, but few have examined its association with the outcomes of natural 
conception.26,27 For this reason, studies examining the association between serum AMH levels 
and artificial insemination and/or in vitro fertilization outcomes were excluded. In order to better 
isolate the relationship between ovarian reserve and pregnancy loss, studies examining recurrent 
miscarriages were also excluded. Non-English studies were excluded from the review to 
eliminate the consequences of misinterpretation. 
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Information Sources and Search: 
This study was conducted according to the PRISMA guidelines. Electronic searches 
using Pubmed, Scopus, and ClinicalTrials.gov were performed on March 29, 2018. Search terms 
included “Anti mullerian hormone,” “antimullerian hormone,” “anti-mullerian hormone,” 
“AMH,” “diminished ovarian reserve,” and“decreased ovarian reserve” in combination with 
“miscarriage,” “miscarriages,” “pregnancy loss,” and “pregnancy losses.” Data compilation was 
performed using the Covidence systematic review software (Covidence systematic review 
software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org). 
Searches were conducted with assistance from a health services librarian. 
Study Selection: 
Studies identified by database searches were imported into Covidence. Duplicate articles 
were identified and removed. All titles and abstracts from searches were reviewed by one author. 
Full-texts of articles labeled as potentially eligible at the abstract phase were reviewed again for 
eligibility using the same criteria (Table 1). 
Data Abstraction: 
For all included studies, relevant data was abstracted by one author. The following 
information was abstracted from each included study: year of patient enrollment, study design, 
study site (single versus multicenter), country, primary purpose, inclusion criteria, exclusion 
criteria, patient population, mean age, mean BMI, mean serum AMH levels, definition of “low 
AMH,” number of women classified as having low AMH, cycle day at which AMH was 
measured, and study conclusions. 
Risk of Bias and Synthesis of Results: 
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Each study was evaluated for its potential bias, including risk of confounding, 
measurement bias, and selection bias, and rated as either “Low,” “Medium,” or “High.” These 
findings were used to grade the quality of each study as either “Good,” “Moderate,” or “Poor.” 
Given the heterogeneity of measures, study results were not combined quantitatively. 
RESULTS 
Study Selection: 
The initial literature search yielded 157 articles (60 were found to be duplicates). Figure 1 
shows details of the literature review. After review of title and abstracts, the full-texts of 34 
potentially eligible articles were reviewed again for eligibility. Reasons for exclusion at the full-
text stage are shown in Figure 1. After review of all potentially eligible full-texts, only one study 
met inclusion criteria.  
Study Characteristics: 
 The one included study by Zarek et al. is a secondary analysis of data from the EAGeR 
Trial; EAGeR is a randomized trial of low dose aspirin in gestation and reproduction (Table 2).28 
This analysis was a prospective cohort of 1228 women from the EAGeR trial who had one to 
two previous pregnancy losses. Of these, 708 participants achieved a clinical pregnancy and had 
a documented AMH measurement. AMH levels were categorized as low (< 1.00 ng/ml), normal 
(1.00-3.5 ng/ml), and high (> 3.5 ng/ml) and compared using log binomial models. Zarek et al. 
found no significant association between AMH levels and pregnancy loss, in both unadjusted and 
adjusted models.28 
 Overall, the study has low risk of bias. There are not major concerns about confounding, 
selection bias, or measurement bias.  
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There are some concerns with the external validity since the study population is not 
representative of the US as a whole, as only four clinical sites were used for recruitment. 
Association between AMH Levels and Pregnancy Loss: 
Zarek et al. found no association between low serum AMH levels and pregnancy loss. 
These results are unlikely to be biased by potential confounders, as all models were adjusted for 
age, race, BMI, treatment, number of previous pregnancy losses, recency of loss, parity, and 
income. In addition, the EAGeR Trial controlled for confounding using block randomization and 
a double-blind, placebo-controlled study design. Once no associations were found between AMH 
and pregnancy loss, the study authors further stratified the results by the number of prior live 
births, prior pregnancy losses, and recency of loss. The results remained negative after said 
adjustments, further strengthening the findings. 
Overall the potential for selection bias was also found to be low, but there was some 
concern for the external validity. The original study population was randomized, but the 
prospective cohort design of the substudy took away some of the advantages of randomization. 
For example, the original study recruited individuals from four clinical sites across the country. 
Although these cities varied in size and location, over 95% of the population in Zarek et al. were 
white with over a high school education. This makes the applicability of the study results 
minimal, as this certainly does not represent the United States as a whole. Zarek et al., however, 
adjusted their selection process to only include those with one to two previous pregnancy losses. 
By excluding women with recurrent pregnancy loss, the risk of confounding and selection bias is 
reduced, as results are not skewed by women with underlying fertility issues. Lastly, while some 
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may be concerned with the initial comparability of study groups, the prospective design of this 
study makes it unnecessary, and impossible, to create equal groups. Instead, the study authors 
appropriately adjusted for the discrepancies in their final models, eliminating the concern for 
selection bias.  
The risk of measurement bias was also minimal in Zarek et al. The study referenced the 
description of the methods in the original study as well as described the measurement processes 
in the manuscript. Where, when, and how the AMH levels were drawn were clearly outlined and 
performed to the standards of several other studies measuring similar serum levels. In addition, 
the definition of pregnancy and pregnancy loss were clearly detailed and consistent.   
DISCUSSION 
Summary of Evidence: 
In the one study that met eligibility criteria, low serum AMH, as a marker of diminished 
ovarian reserve, was not associated with pregnancy loss. Several studies examine the relationship 
between AMH and recurrent pregnancy loss, which can be easily confounded by other risk 
factors for infertility. To our knowledge, Zarek et al. were the only authors to conduct study 
solely examining the association between AMH and pregnancy loss. This US study did an 
excellent job adjusting for confounders and minimizing both selection and measurement bias. 
Although the external validity of the study is limited, there were no significant concerns about 
other risk of bias domains. 
Although Zarek et al.’s study was informative and impartial, the lack of other studies 
reporting on this relationship limits the ability to make a strong conclusion. The influence of 
diminished ovarian reserve remains uncertain and should continue to be investigated in future 
studies in order to inform clinical practice. Understanding the true meaning of these biomarkers 
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will help to aid both physicians and patients make clinical decisions with regards to fertility 
treatments. 
Limitations: 
A major limitation of this review is the lack of dual review of the literature, data 
abstraction, and risk of bias assessment. Having only one investigator creates the risk of 
incomplete retrieval of research as well as possible reporting bias given the lack of diverse 
perspectives and interpretation of the available data. There is also potential bias in excluding all 
non-English articles. 
Conclusions: 
This review found only one relevant study investigating the relationship between serum 
AMH and pregnancy loss. This study found no association between diminished ovarian reserve, 
as defined as low serum AMH, and pregnancy loss. Further investigation of this relationship is 
warranted to better understand the influence of diminished ovarian reserve on the ability to 
achieve and maintain pregnancy.  
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Appendix 2a:  
 
Table 1: Study Inclusion and Exclusion Criteria 
 
 Inclusion Criteria Exclusion Criteria 
Population Women of all ages Studies without human subjects 
Exposure Diminished ovarian reserve as indicated by low serum AMH levels - 
Comparators Women with normal serum AMH levels - 
Outcomes Pregnancy loss after natural fertilization 
Studies examining assisted 
fertility 
Studies examining recurrent 
miscarriages 
Timing No time exclusions - 
Settings All Countries - 
Study Designs All observational studies Case reports, editorials, clinical trials 
Language English Non-English 
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Figure 1: PRISMA Diagram 
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Table 2: Results Extraction 
Citation Zarek SM, Mitchell EM, Sjaarda LA, et al. Antimüllerian hormone 
and pregnancy loss from the Effects of Aspirin in Gestation and 
Reproduction trial. Fertil Steril. 2016;105(4):946-952.e2. 
doi:10.1016/j.fertnstert.2015.12.003. 
Year of 
enrollment 
2006 
Study design Prospective cohort study using data from a randomized control trial 
Study site Four US Clinical Sites (Salt Lake City, UT; Buffalo, NY; Scranton, 
PA; Denver, CO) 
Country United States 
Primary purpose To investigate if AMH is associated with pregnancy loss 
Inclusion criteria Age 18-40 years; attempting pregnancy; regular menstrual cycles; no 
history of infertility, PCOS, tubal blockage, PID, endometriosis, 
uterine abnormalities, anovulation; history of 1-2 previous pregnancy 
losses 
Exclusion criteria Exclusion criteria from EAGeR Trial: known allergy to NSAIDs or 
ASA; clinical indication for anticoagulant therapy, chronic NSAID 
use, or folic acid supplements; medical contraindication for ASA; 
major medical disorders or unstable mental disorder; undergoing or 
planning to use fertility treatments during study; history of subfertility 
or infertility; current or recent illicit drug use or alcohol abuse; 
temporary exclusion for current diagnosis of STI 
Patient 
population 
1228 women of reproductive age enrolled in the EAGeR Trial with 
history of one to two previous pregnancy losses 
Mean age 28.7 (± 4.6) 
Mean bmi 25.5 kg/m2 (± 6.1) 
Mean amh (Range 0.07 - 22.1 ng/ml) 
Definition of 
“low amh” 
< 1.00 ng/ml 
Women with 
Low amh 
73 of 708 participants who achieved a clinical pregnancy with a 
measured AMH level 
Cycle day at 
which amh was 
measured 
Day 2-4 of the menstrual cycle 
Conclusions There was no significant association between AMH levels and 
pregnancy loss 
Confounding Low 
Measurement 
bias 
Low 
Selection bias Low 
 
 
